RWM
PTGX icon

Raffa Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Raffa Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.36K Hold
60
– – ﹤0.01% 502
2026
Q1 		$6.32K Hold
60
– – ﹤0.01% 484
2025
Q4 		$5.24K Hold
60
– – ﹤0.01% 512
2025
Q3 		$3.99K Hold
60
– – ﹤0.01% 529
2025
Q2 		$3.32K Buy
+60
New +$2.88K ﹤0.01% 582

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Raffa Wealth Management's PTGX Position: Q2 2026 in Review

Raffa Wealth Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 60 shares worth $7.36K. The position accounts for ﹤0.01% of the portfolio, ranked #502.

Raffa Wealth Management first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Raffa Wealth Management held 60 shares of Protagonist Therapeutics worth $7.36K as of Q2 2026.
  • Raffa Wealth Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Raffa Wealth Management's portfolio in Q2 2026, its #502 holding.
  • Raffa Wealth Management first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Raffa Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.